Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in TaxesChange in TaxesChange in Working CapitalChange in Working CapitalDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet Income
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Trinity Biotech (TRIB) Change in Cash (2021 - 2024)

Trinity Biotech recorded quarterly Change in Cash of $2.4 million in Q4 2024, up 200.29% quarter-over-quarter from -$2.4 million in Q4 2023, and up 200.29% year-over-year from $805554.1 in Q1 2024.

Trinity Biotech's Change in Cash history runs 4 years deep, the most recent figure standing at $2.4 million for Q4 2024.

  • In Q4 2024, Change in Cash rose 200.29% year-over-year to $2.4 million; the TTM figure through Dec 2024 stood at -$8.7 million (up 38.52% YoY), while the FY2025 annual figure was -$100000.0, down 105.88% from the prior year.
  • Change in Cash came in at $2.4 million for Q4 2024 at Trinity Biotech, up from -$2.4 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $2.4 million in Q4 2024 to a low of -$8.0 million in Q3 2023.
  • A 4-year average of -$2.2 million and a median of -$2.1 million in 2021 frame the typical range for Change in Cash.
  • Across the five-year window, Change in Cash plunged 240.68% in 2023 and jumped 200.29% in 2024, its largest moves.
  • Trinity Biotech's Change in Cash stood at -$1.7 million in 2021, then surged by 59.12% to -$708000.0 in 2022, then slumped by 240.68% to -$2.4 million in 2023, then surged by 200.29% to $2.4 million in 2024.
  • According to Business Quant data, Change in Cash over the past three periods registered $2.4 million, -$2.4 million, and -$8.0 million for Q4 2024, Q4 2023, and Q3 2023 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Cash (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn -1.72 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -1.13 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -136.00 Mn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -504.00 Mn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -492.00 Mn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn 199.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -2.23 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 15.90 Mn
10 Trinity Biotech 28,000.00 -5.11 Mn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2024 2.42 Mn
Dec 31, 2023 -2.41 Mn
Sep 30, 2023 -7.98 Mn
Dec 31, 2022 -708,000.00
Sep 30, 2022 -3.02 Mn
Dec 31, 2021 -1.73 Mn